Vigil Neuroscience, Inc. (VIGL)
NASDAQ: VIGL · Real-Time Price · USD
7.99
+0.01 (0.13%)
Jul 3, 2025, 1:00 PM - Market closed
Vigil Neuroscience Employees
Vigil Neuroscience had 69 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
69
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,256,942
Market Cap
380.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69 | 0 | - |
| Dec 31, 2023 | 69 | 13 | 23.21% |
| Dec 31, 2022 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VIGL News
- 4 weeks ago - Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP - GlobeNewsWire
- 6 weeks ago - VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL - Business Wire
- 6 weeks ago - Sanofi to Buy Vigil Neuroscience for About $470 Million - WSJ
- 6 weeks ago - Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi - GlobeNewsWire
- 6 weeks ago - Sanofi to acquire Vigil Neuroscience in $470 million deal - Reuters
- 6 weeks ago - Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline - GlobeNewsWire
- 2 months ago - Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates - GlobeNewsWire
- 3 months ago - Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference - GlobeNewsWire